

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person. **DO NOT EXCEED FIVE PAGES.**

NAME: Wei-Jen Tang

eRA COMMONS USER NAME (credential, e.g., agency login): WEI-JEN

POSITION TITLE: Professor

EDUCATION/TRAINING *(Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.)*

INSTITUTION AND LOCATION	DEGREE (if applicable)	Completion Date MM/YYYY	FIELD OF STUDY
National Taiwan University	B.S.	10/1978-05/1982	Zoology
University of Texas, Austin	Ph.D.	08/1984-05/1988	Biological Science (Mentor: William R. Folk)
University of Texas, Austin	Postdoctoral fellow	06/1988-08/1988	Microbiology (Mentor: William R. Folk)
University of Texas Southwestern Medical School	Postdoctoral fellow	09/1988-06/1991	Pharmacology (Mentor: Alfred G. Gilman)

A. Personal Statement

My research program involves in elucidating the molecular basis of protein functions relevant to human health and diseases. The research is based on the premise that the better understanding of protein-protein and protein-ligand interaction is key to elucidating the fundamental principles governing cellular signaling network that contributes to normal physiological and pathological settings. I apply structure biological (e.g., X-ray crystallography and single particle EM), proteomics, biochemical, biophysical, cellular and pharmacological tools to address the protein functions and regulations. I am known for the studies on the catalysis and regulation of mammalian adenylyl cyclase, anthrax and pertussis adenylyl cyclase toxins, and human insulin degrading enzyme (IDE). I am also known in the drug discovery for anthrax toxins, edema factor and lethal factor, and human insulin degrading enzyme. I am a strong believer of collaboration, which shows nicely from the collaborative nature of many research projects in my publications. An example is my effort to assemble a team of researchers from academy and industry to show the efficacy of approved antiviral drug, Adefovir in inhibiting anthrax edema factor and anthrax pathogenesis. This allows the repurpose of the existing anti-hepatitis B virus drug for the biodefense against anthrax bacterium, a bioweapon for mass destruction and a proven bioterrorism agent used in 2001. The other example is the involvement of my lab with many scientific teams to develop the small molecule modulators of human IDE. IDE plays the key role in the clearance of insulin and amyloid β thus is vital for the progression of type 2 diabetes and Alzheimer's disease. The small molecule modulators could be further developed for the treatment of these chronic diseases that are continuing in the rise.

a. **Tang, W.-J.** & Gilman, A. G. (1991) Type-specific regulation of adenylyl cyclase by G protein $\beta\gamma$ subunits. *Science* 254:1500-1503.

b. Drum, C.L., Yan, S.-Z., Bard, J., Shen, Y.-Q., Lu, D., Soelaiman, S., Grabarek, Z., Bohm, A., & **Tang, W.-J.** (2002) Structural basis for the activation of anthrax adenylyl cyclase exotoxin by calmodulin. *Nature* 415:396-402. (Highlighted in N&V *Nature* 415: 373, 2002; N & V *Nature Structure Biology* 9:156, 2002; Minireview *Cell* 108:739, 2002)

c. Shen, Y.-Q., Zhukovskaya, N.L., Zimmer, M.I., Soelaiman, S., Wang, C.R., Gibbs, C.S., & **Tang, W.-J.** (2004) Selective inhibition of anthrax edema factor by adefovir, a drug for chronic hepatitis B virus infection. *Proc. Natl. Acad. Sci. U.S.A.* 101:3242-3247.

d. Shen, Y., Joachimiak, A., Rosner, M.R., & **Tang, W.-J.** (2006) Structures of human insulin degrading enzyme reveal a new substrate recognition mechanism. *Nature* 443:870-874. (Highlighted in N&V *Nature* 443:761, 2006).

B. Positions and Honors

Positions and Employment

1982-1984	Lieutenant, Air Force, Taiwan
1991-1993	Instructor, Dept. of Pharmacology, University of Texas Southwestern Medical School
1993-1994	Assistant Professor, Dept. of Pharmacology, UT Southwestern Medical School
1994-1998	Assistant Professor, Dept. of Pharmacol. & Physiol. Sciences, The University of Chicago
1998-2001	Assistant Professor, Dept. of Neurobiol. Pharmacol. & Physiol., The University of Chicago
2001-2007	Associate Professor, Ben-May Institute for Cancer Research, The University of Chicago
2007-present	Professor, Ben-May Department for Cancer Research, The University of Chicago

Other Experience and Professional Memberships

1992-present	American Society for Biochemistry and Molecular Biology
1986-2013	American Association for the Advancement of Science
1998-present	Ad Hoc NIH and NSF grant reviewing panels
2007-2011	Regular member of NIH MSF-C study section
2009	The advisory Board, Structure Biology Center, APS, Argonne National Lab.
2012-2014	Regular member of American Heart Association Signaling 4 study section.

Honors

1987-1988	University Fellowship, University of Texas, Austin
1999-2002	American Heart Association Established Investigator

C. Contributions to Science

1. Regulation and catalysis of mammalian adenylyl cyclases: Cyclic AMP is a prototypic intracellular second messenger that controls diverse physiological events in response to the stimulation of a plethora of hormones and neurotransmitters. My early publications establish the molecular basis for the regulation and catalysis of mammalian adenylyl cyclase, which is an enzyme that raises the intracellular cyclic AMP level in response to the extracellular stimuli. Upon the activation by G protein coupled receptors, hormone-regulated heterotrimeric G protein is dissociated into α and $\beta\gamma$ subunits. The dogma at the time is that α subunit of G protein, but not $\beta\gamma$ subunit is responsible to regulate mAC. After involving in the cloning of first mammalian adenylyl cyclase (type 1), I characterized its regulation biochemically to show surprisingly that $\beta\gamma$ can effectively suppress the activity of type 1 adenylyl cyclase. I also subsequently showed that G protein $\beta\gamma$ subunit could directly activate the activity of G_{sa} -activated type 2 adenylyl cyclase. This finding made the seminal contribution to establish the direct roles of G protein $\beta\gamma$ in modulating the activity of downstream effectors. Mammalian membrane-bound adenylyl cyclase consists of two trans-membrane domains, each followed by a conserved cytoplasmic domain. I also have combined protein-engineering and genetic approaches to construct a G_{sa} -activated soluble adenylyl cyclase from two conserved cytoplasmic domains of adenylyl cyclase and used it to address the catalysis and regulation of adenylyl cyclase by G_{sa} and forskolin. As the soluble adenylyl cyclase is amenable to structural analyses, such construct played a key role for the structural studies of mAC. Together, the molecular basis of how mammalian adenylyl cyclases are regulated by G proteins, calmodulin, and other pharmacological agents such as forskolin was elucidated. I was initially a postdoctoral fellow and then a junior faculty under the guidance of Dr. Alfred G. Gilman at UT Southwestern Medical School and then became the principal investigator at the University of Chicago for these studies.

- a. **Tang, W.-J.** & Gilman, A. G. (1991) Type-specific regulation of adenylyl cyclase by G protein $\beta\gamma$ subunits. *Science* 254:1500-1503.
- b. **Tang, W.-J.** & Gilman, A.G. (1995) Forskolin and G_{sa} sensitive soluble adenylyl cyclase. *Science* 268:1769-1772.

- c. Yan, S.-Z., Hahn, D., Huang, Z.-H., & **Tang, W.-J.** (1996) Two cytoplasmic domains of mammalian adenylyl cyclase form a G_{sa} and forskolin-activated enzyme in vitro. *J. Biol. Chem.* 271:10941-10945.
- d. Yan, S.-Z., Huang, Z.-H., Rao, V.D., Hurley, J.H., & **Tang, W.-J.** (1997) Three discrete regions of mammalian adenylyl cyclase form a site for G_{sa} activation. *J. Biol. Chem.* 272:18849-18854.

2. Structural and functional analyses of anthrax edema factor: I have been studying the molecular basis of how toxins and virulent factors disrupt the cellular signal transduction to benefit the bacterial pathogenesis. I have primarily used *Bacillus anthracis*, bacteria that causes anthrax, as the model system. Anthrax bacteria, a bioweapon for mass destruction and a proven bioterrorism agent used in 2001, secrete three major toxins, edema factor (EF), lethal factor (LF), and protective antigen (PA). EF has the calmodulin (CaM)-activated adenylyl cyclase activity. We have determined the structures of EF and EF-CaM complex to address the structural basis of how CaM binds and activates EF, highlighting the diverse mode of binding and mechanism of action of CaM to modulate their effectors. Furthermore, this work reveals that bacterial adenylyl cyclase toxins and eukaryotic adenylyl cyclases use two-metal mediated catalysis despite they share no structural similarity. Advanced Photon Source at Argonne National Laboratory has highlighted our work for their contribution to the biodefense as the structures of EF are the first anthrax toxin solved by the use of synchrotron facility in US. I have led a team to develop and characterize small molecule inhibitors against EF and LF. One example is our teamwork of researchers from academy and industry to show the efficacy of approved antiviral drug, adefovir in inhibiting the activity of EF and anthrax pathogenesis. This allows the repurpose of the existing anti-hepatitis B virus drug against the anthrax infection. I also have done collaborative work to address the roles of EF in anthrax pathogenesis and develop the experimental models to study EF-induced tissue damages.

- a. Drum, C.L., Yan, S.-Z., Bard, J., Shen, Y.-Q., Lu, D., Soelaiman, S., Grabarek, Z., Bohm, A., & **Tang, W.-J.** (2002) Structural basis for the activation of anthrax adenylyl cyclase exotoxin by calmodulin. *Nature* 415:396-402. (Highlighted in *N&V Nature* 415: 373, 2002; *N & V Nature Structure Biology* 9:156, 2002; *Minireview Cell* 108:739, 2002)
- b. Shen, Y.-Q., Zhukovskaya, N.L., Zimmer, M.I., Soelaiman, S., Wang, C.R., Gibbs, C.S., & **Tang, W.-J.** (2004) Selective inhibition of anthrax edema factor by adefovir, a drug for chronic hepatitis B virus infection. *Proc. Natl. Acad. Sci. U.S.A.* 101:3242-3247.
- c. Lee, Y.-S., Bergson, P., He, W.-S., Mrksich, M., & **Tang, W.-J.** (2004) Discovery of a small molecule that inhibits the interaction of anthrax edema factor with its cellular activator, calmodulin. *Chem. & Biol.* 11:1139-46.
- d. Shen, Y., Zhukovskaya, N.L., Guo, Q., Florián, J., and **Tang, W.-J.** (2005) Calcium-independent calmodulin binding and two-metal-ion catalytic mechanism of anthrax edema factor. *EMBO J.* 24:929-941.

3. Structural and functional analyses and drug discovery of human insulin degrading enzyme (IDE) and presequence protease (PreP): Type 2 diabetes mellitus (T2DM) and Alzheimer's disease are human chronic diseases that affect millions of people in US alone. Aberrant levels of insulin and improper responses to insulin and other hormones that control glucose levels are the primary causes of T2DM. A β peptide, the primary component in amyloid plaques, plays a central role in the progression of AD. Insulin Degrading Enzyme (IDE) and Presequence Protease (PreP) are structurally related, ~110 kDa M16 Zn²⁺-metalloproteases that use an enclosed catalytic chamber to recognize and degrade peptide substrates into fragments. IDE is involved in the clearance of peptides diverse in structure and sequence, including three glucose-regulating hormones (insulin, amylin, and glucagon), A β , and other bioactive peptides <80 aa. The involvement of IDE in the clearance of insulin and A β links IDE to the progression of Type 2 diabetes mellitus and Alzheimer's disease. PreP is localized at mitochondrial matrix, where it degrades presequences cleaved from proteins imported into the organelle. PreP also effectively degrades A β *in vitro* and may degrade A β imported into mitochondria to prevent A β toxicity in mitochondria. The defect in PreP is embryonic lethal in mice and is linked to the neurological disorder such as mental retardation and spinocerebellar ataxia. I have used structural, biochemical, and biophysical analyses to construct a working model to how human IDE and PreP use their catalytic chambers to recognize the <80 aa substrates in a distinct manner. We also decipher the molecular basis of how IDE recognizes amyloidogenic peptides. Furthermore, we have developed potent inhibitors of human IDE and PreP to explore the biological

functions and therapeutic potential of these proteases. Together, our studies pave the way to explore IDE and PreP-based therapies.

- a. Shen, Y., Joachimiak, A., Rosner, M.R., & **Tang, W.-J.** (2006) Structures of human insulin degrading enzyme reveal a new substrate recognition mechanism. *Nature* 443:870-874. (Highlighted in N&V *Nature* 443:761, 2006)
- b. McCord L.A., Liang, W.G., Dowdell, E., Kalas, V., Hoey, R.J., Koide, A., Koide, S., & **Tang, W.-J.** (2013) Conformational states and recognition of amyloidogenic peptides of human insulin-degrading enzyme. *Proc. Natl. Acad. Sci. USA* 110(34):13827-32.
- c. King, J.V., Liang, W.G., Scherpelz, K.P., Schilling, A.B., Meredith, S.C., & **Tang, W.-J.** (2014) Molecular basis of substrate recognition and degradation by human presequence protease. *Structure* 22:996-1007.
- d. Maianti, J.P., McFedries, A., Foda, Z.H., Kleiner, R.E., Du, X.-Q., **Tang, W.-J.**, Charron, M.J., Seeliger, M.A., Saghatellian, A., & Liu, D.R. (2014) Anti-diabetic activity of insulin degrading enzyme inhibitors mediated by multiple hormones. *Nature* 511:94-98. (Previewed by *Cell Metabolism* 20:201, 2014).
- e. Zheng, Z., Liang, W.G., Bailey, L.J., Tan, Y.Z., Wei, H., Wang, A., Farcasanu, M., Woods, V.A., McCord, L. A., Lee, D., Shang, W., Deprez-Poulain, R., Deprez, B., Liu, D.R., Koide, A., Koide, S., Kossiakoff, A.A., Li, S.*, Carragher*, B., Potter, C.S.*, and **Tang, W.-J.***, (2018) Ensemble cryoEM elucidates the mechanism of insulin capture and degradation by human insulin degrading enzyme. *ELife* 7:e33572 (*co-corresponding authors).

4. Structural and functional analyses of human chemokines Chemokines are 8-14 kDa chemotactic cytokines that modulate inflammation and infection, affecting many chronic human diseases and thus potential therapeutic targets. CCL3 (a.k.a. MIP-1 α), CCL4 (a.k.a. MIP-1 β), CCL5 (a.k.a. RANTES) are proinflammatory chemokine that are linked to many human diseases, e.g., atherosclerosis, AIDS, and cancer. These chemokines readily dimerize and then form high molecular weight, >500 kDa oligomers. Our structural studies reveal how these chemokines form the rod-shaped, double helical oligomers and how oligomerization regulates their functions at the ligand level. Glycosaminoglycans (GAGs) are complex polysaccharides that are either free or attached to proteoglycans that are present at the glycocalyx layer of the cell surface or in the extracellular matrix. The binding of chemokines to extracellular GAG is a key for chemokines' function. Our GAG bound CCL3 and CCL5 structures also provide the structural basis of how GAG binds these chemokines, which allows further exploration how GAG regulates chemokine functions.

- a. Ren, M., Guo, Q., Guo, L., Lenz, M., Qian, F., Koenen, R.R., Xu, H., Schilling, A.B., Weber, C., Ye, R.D., Dinner, A.R., and **Tang, W.-J.** (2010) Polymerization of MIP-1 chemokine (CCL-3 and CCL-4) and clearance of MIP-1 by insulin degrading enzyme. *EMBO J.* 29:3952-3966.
- b. Liang, W.G., Ren, M., Zhao, F., and **Tang, W.-J.** (2015) Structures of human CCL18, CCL3, and CCL4 reveal molecular determinants for quaternary structures and sensitivity to insulin degrading enzyme. *J. Mol Biol* 427:1345-1358.
- c. Liang WG, Triandafillou CG, Huang T-Y, Zulueta MML, Banerjee S, Dinner AR, Hung S-C, & **Tang W.-J.** (2016) Structural basis for oligomerization and glycosaminoglycan-binding of CCL5 and CCL3. *Proc Natl Acad Sci USA* 113:5000-5005.

5. Structural and functional analyses of bacterial virulent factors: In addition to study the virulent factors secreted by anthrax bacteria, I have also done biochemical and structural analyses of CaM-activated adenylyl cyclase toxin secreted by *Bordetella pertussis*, bacteria that cause whooping cough. Our studies led to the surprising finding that the mode of CaM binding by pertussis adenylyl cyclase toxin is completely different from that of EF, highlighting that the diverse means that CaM effectors can evolve to be regulated by CaM. I have the broad interest in the structure and functions of bacterial toxins. Toward this, I have determined the structure of anthrolysin O, an anthrax-secreted, pore-forming toxin and shown that anthrolysin O can disrupt the integrity of gut epithelial monolayer, thus potentially contributing to gastrointestinal anthrax. I have also involved in studying an anthrax-secreted protease, inhA and showed that inhA interferes blood coagulation in the quorum-acting manner.

- a. Guo, Q., Shen, Y., Lee, Y.-S., Gibbs, C.S., Mrksich, M., & **Tang, W.-J.** (2005) Structural basis for the interaction of adenylyl cyclase toxin of *Bordetella pertussis* with calmodulin. *EMBO J.* 24:3190-3201.
- b. Bourdeau, R.W., Malito, E., Chenal, A., Bishop, B.L., Musch, M.W., Villereal, M.L., Chang, E.B., Mosser,

- E.M., Rest, R.F., & **Tang, W.J.** (2009) Cellular functions and X-ray structure of anthrolysin O, a cholesterol-dependent cytolysin secreted by *Bacillus anthracis*. J. Biol. Chem. 284:14645-56.
- c. Bishop, B.L. Lodolce, J.P., Kolodziej, L.E., Boone, D.L., & **Tang, W.J.** (2010) The role of anthrolysin O in gut epithelial barrier disruption during *Bacillus anthracis* infection. Biochem. Biophys. Res. Commun. 394:254-259.
- d. Kastrop, C.J., Boedicker, J.Q., Pomerantsev, A.P., Moayeri, M., Bian, Y., Pompano, R.R., Kline, T.R., Sylvestre, P., Shen, F., Leppla, S.H., **Tang, W.-J.**, & Ismagilov, R.F. (2008) Spatial localization of bacteria controls coagulation of human blood by 'quorum acting'. Nature Chem Biol 4:742-750.

Complete List of Published Work in MyBibliography:

http://www.ncbi.nlm.nih.gov/sites/myncbi/1b5sZCJCab_kp/bibliography/44138238/public/?sort=date&direction=descending

D. Research Support

Ongoing Research Support

R01 GM 121964	Tang (PI)	09/01/2017-08/31/2021
NIH NIGMS		

Structure-function analysis and small molecule modulator discovery of human insulin degrading enzyme

This study is to analyze molecular basis of how human insulin degrading enzyme undergoes the requisite conformational changes for substrate recognition and destruction as well as to develop the small molecule modulators that can either enhance or inhibit the activity of human insulin degrading enzyme.

Completed Research Support (within past three years)

R01 GM81539-08	Tang (PI)	10/01/2011-09/30/2016
NIH NIGMS		

Regulation and catalysis of human insulin degrading enzyme

This study is to analyze molecular basis for substrate recognition and regulation of human insulin degrading enzyme.

Grant-in-Aid 17GRNT33400028	Tang (PI)	01/01/2017-12/31/2018
American Heart Association		

Structure and functions of chemokine CCL5-CXCL4 hetero-oligomer

This study is to use biophysical and structural methods to investigate the molecular basis of heteromer formation between CCL5 and CXCL4.